Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 3681094, 14 pages
http://dx.doi.org/10.1155/2016/3681094
Review Article

Microbial and Natural Metabolites That Inhibit Splicing: A Powerful Alternative for Cancer Treatment

1Laboratorio de Ecología Molecular Microbiana, Centro de Investigaciones en Ciencias Microbiológicas, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Edificio IC11, Ciudad Universitaria, 72570 Colonia San Manuel, PUE, Mexico
2Laboratorio de Bioquímica y Biología Molecular, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Edificio 103H, Ciudad Universitaria, 72550 Colonia San Manuel, PUE, Mexico
3Posgrado en Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Edificio 105 I, Ciudad Universitaria, 72570 Colonia San Manuel, PUE, Mexico

Received 19 March 2016; Revised 27 June 2016; Accepted 3 July 2016

Academic Editor: Yiannis Kourkoutas

Copyright © 2016 Nancy Martínez-Montiel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Jurica and M. J. Moore, “Pre-mRNA splicing: awash in a sea of proteins,” Molecular Cell, vol. 12, no. 1, pp. 5–14, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. A. J. Matlin, F. Clark, and C. W. J. Smith, “Understanding alternative splicing: towards a cellular code,” Nature Reviews Molecular Cell Biology, vol. 6, no. 5, pp. 386–398, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. C. L. Will and R. Lührmann, “Spliceosomal UsnRNP biogenesis, structure and function,” Current Opinion in Cell Biology, vol. 13, no. 3, pp. 290–301, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. B. K. Das, L. Xia, L. Palandjian, O. Gozani, Y. Chyung, and R. Reed, “Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155,” Molecular and Cellular Biology, vol. 19, no. 10, pp. 6796–6802, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Krämer, P. Grüter, K. Gröning, and B. Kastner, “Combined biochemical and electron microscopic analyses reveal the architecture of the mammalian U2 snRNP,” Journal of Cell Biology, vol. 145, no. 7, pp. 1355–1368, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Brosi, H.-P. Hauri, and A. Kramer, “Separation of splicing factor SF3 into two components and purification of SF3a activity,” The Journal of Biological Chemistry, vol. 268, no. 23, pp. 17640–17646, 1993. View at Google Scholar · View at Scopus
  7. M. C. Wahl, C. L. Will, and R. Lührmann, “The spliceosome: design principles of a dynamic RNP machine,” Cell, vol. 136, no. 4, pp. 701–718, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. K. R. Thickman, M. C. Swenson, J. M. Kabogo, Z. Gryczynski, and C. L. Kielkopf, “Multiple U2AF65 binding sites within SF3b155: thermodynamic and spectroscopic characterization of protein-protein interactions among pre-mRNA splicing factors,” Journal of Molecular Biology, vol. 356, no. 3, pp. 664–683, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Nakajima, Y. Hori, H. Terano et al., “New antitumor substances, FR901463, FR901464 and FR901465: II. Activities against experimental tumors in mice and mechanism of action,” Journal of Antibiotics, vol. 49, no. 12, pp. 1204–1211, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Corrionero, B. Miñana, and J. Valcárcel, “Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A,” Genes and Development, vol. 25, no. 5, pp. 445–459, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Kaida, H. Motoyoshi, E. Tashiro et al., “Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA,” Nature Chemical Biology, vol. 3, no. 9, pp. 576–583, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. G. A. Roybal and M. S. Jurica, “Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation,” Nucleic Acids Research, vol. 38, no. 19, Article ID gkq494, pp. 6664–6672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Kotake, K. Sagane, T. Owa et al., “Splicing factor SF3b as a target of the antitumor natural product pladienolide,” Nature Chemical Biology, vol. 3, no. 9, pp. 570–575, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. G. Folco, K. E. Coil, and R. Reed, “The anti-tumor drug E7107 reveals an essential role for SF3b in remodeling U2 snRNP to expose the branch point-binding region,” Genes & Development, vol. 25, no. 5, pp. 440–444, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Sakai, T. Tsujita, T. Akiyama et al., “GEX1 compounds, novel antitumor antibiotics related to herboxidene, produced by Streptomyces sp. II. The effects on cell cycle progression and gene expression,” Journal of Antibiotics, vol. 55, no. 10, pp. 863–872, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Hasegawa, T. Miura, K. Kuzuya et al., “Identification of SAP155 as the target of GEX1A (Herboxidiene), an antitumor natural product,” ACS Chemical Biology, vol. 6, no. 3, pp. 229–233, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. G.-Z. Zeng, N.-H. Tan, X.-J. Hao, Q.-Z. Mu, and R.-T. Li, “Natural inhibitors targeting osteoclast-mediated bone resorption,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 24, pp. 6178–6180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. S.-O. Yoon, S. Shin, H.-J. Lee, H.-K. Chun, and A.-S. Chung, “Isoginkgetin inhibits tumor cell invasion by regulating phosphatidylinositol 3-kinase/Akt-dependent matrix metalloproteinase-9 expression,” Molecular Cancer Therapeutics, vol. 5, no. 11, pp. 2666–2675, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Heinhuis, T. S. Plantinga, G. Semango et al., “Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines,” Carcinogenesis, vol. 37, no. 2, pp. 197–205, 2016. View at Publisher · View at Google Scholar
  20. Y. Mizui, T. Sakai, M. Iwata et al., “Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities,” Journal of Antibiotics, vol. 57, no. 3, pp. 188–196, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Yokoi, Y. Kotake, K. Takahashi et al., “Biological validation that SF3b is a target of the antitumor macrolide pladienolide,” FEBS Journal, vol. 278, no. 24, pp. 4870–4880, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Sato, N. Muguruma, T. Nakagawa et al., “High antitumor activity of pladienolide B and its derivative in gastric cancer,” Cancer Science, vol. 105, no. 1, pp. 110–116, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. M. K. Kashyap, D. Kumar, R. Villa et al., “Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B,” Haematologica, vol. 100, no. 7, pp. 945–954, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. F. A. L. M. Eskens, F. J. Ramos, H. Burger et al., “Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors,” Clinical Cancer Research, vol. 19, no. 22, pp. 6296–6304, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Iwata, I. Ozawa, T. Uenaka et al., “E7107, a new 7-urethane derivative of pladienolide D, displays curative effect against several human tumor xenografts,” Proceedings of the American Association for Cancer Research, vol. 64, no. 7, supplement, p. 691, 2014. View at Google Scholar
  26. J. M. Johnson, J. Castle, P. Garrett-Engele et al., “Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays,” Science, vol. 302, no. 5653, pp. 2141–2144, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Tazi, N. Bakkour, and S. Stamm, “Alternative splicing and disease,” Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, vol. 1792, no. 1, pp. 14–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Chabot and L. Shkreta, “Defective control of pre–messenger RNA splicing in human disease,” The Journal of Cell Biology, vol. 212, no. 1, pp. 13–27, 2016. View at Publisher · View at Google Scholar
  29. S. Bonomi, S. Gallo, M. Catillo, D. Pignataro, G. Biamonti, and C. Ghigna, “Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy,” International Journal of Cell Biology, vol. 2013, Article ID 962038, 17 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Ladomery, “Aberrant alternative splicing is another hallmark of cancer,” International Journal of Cell Biology, vol. 2013, Article ID 463786, 6 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. R. M. Hagen and M. R. Ladomery, “Role of splice variants in the metastatic progression of prostate cancer,” Biochemical Society Transactions, vol. 40, no. 4, pp. 870–874, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Oltean and D. O. Bates, “Hallmarks of alternative splicing in cancer,” Oncogene, vol. 33, pp. 5311–5318, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Martínez-Montiel, N. Rosas-Murrieta, and R. Martínez-Contreras, “Alternative splicing regulation: implications in cancer diagnosis and treatment,” Medicina Clinica, vol. 144, no. 7, pp. 317–323, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Contreras Rebeca and M. Montiel Nancy, “Alternative splicing modification as a treatment for genetic disorders,” Gene Technology, vol. 4, article 126, pp. 1–4, 2015. View at Publisher · View at Google Scholar
  35. R. D. Martínez-Contreras and N. Martínez-Montiel, “The role of splicing factors in cancer prognosis and treatment,” in Alternative Splicing and Disease, E. Massey, Ed., Nova Science, New York, NY, USA, 2016. View at Google Scholar
  36. S. Bonnal, L. Vigevani, and J. Valcárcel, “The spliceosome as a target of novel antitumour drugs,” Nature Reviews Drug Discovery, vol. 11, no. 11, pp. 847–859, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Sakai, N. Asai, A. Okuda, N. Kawamura, and Y. Mizui, “Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. II. Physico-chemical properties and structure elucidation,” The Journal of Antibiotics, vol. 57, no. 3, pp. 180–187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. S. S. Kang, J. S. Kim, and W. J. Kawk, “Flavonoids from Ginkgo biloba leaves,” Korean Journal of Pharmacognosy, vol. 21, pp. 111–120, 1990. View at Google Scholar
  39. L. Fan, C. Lagisetti, C. C. Edwards, T. R. Webb, and P. M. Potter, “Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing,” ACS Chemical Biology, vol. 6, no. 6, pp. 582–589, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Motoyoshi, M. Horigome, K. Ishigami et al., “Structure-activity relationship for FR901464: a versatile method for the conversion and preparation of biologically active biotinylated probes,” Bioscience, Biotechnology and Biochemistry, vol. 68, no. 10, pp. 2178–2182, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. A. K. Ghosh and Z.-H. Chen, “Enantioselective syntheses of FR901464 and spliceostatin A: potent inhibitors of spliceosome,” Organic Letters, vol. 15, no. 19, pp. 5088–5091, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. A. K. Ghosh, Z.-H. Chen, K. A. Effenberger, and M. S. Jurica, “Enantioselective total syntheses of fr901464 and spliceostatin A and evaluation of splicing activity of key derivatives,” Journal of Organic Chemistry, vol. 79, no. 12, pp. 5697–5709, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. X. Liu, S. Biswas, G.-L. Tang, and Y.-Q. Cheng, “Isolation and characterization of spliceostatin B, a new analogue of FR901464, from Pseudomonas sp. No. 2663,” Journal of Antibiotics, vol. 66, no. 9, pp. 555–558, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Osman, B. J. Albert, Y. Wang, M. Li, N. L. Czaicki, and K. Koide, “Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464,” Chemistry, vol. 17, no. 3, pp. 895–904, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983. View at Publisher · View at Google Scholar · View at Scopus
  46. H. He, A. S. Ratnayake, J. E. Janso et al., “Cytotoxic spliceostatins from Burkholderia sp. and their semisynthetic analogues,” Journal of Natural Products, vol. 77, no. 8, pp. 1864–1870, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. X. Liu, S. Biswas, M. G. Berg et al., “Genomics-guided discovery of thailanstatins A, B, and C as pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43,” Journal of Natural Products, vol. 76, no. 4, pp. 685–693, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Schneider-Poetsch, T. Usui, D. Kaida, and M. Yoshida, “Garbled messages and corrupted translations,” Nature Chemical Biology, vol. 6, no. 3, pp. 189–198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Pham and K. Koide, “Discoveries, target identifications, and biological applications of natural products that inhibit splicing factor 3B subunit 1,” Natural Product Reports, vol. 33, no. 5, pp. 637–647, 2016. View at Publisher · View at Google Scholar
  50. C. Blancher and A. L. Harris, “The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target,” Cancer and Metastasis Reviews, vol. 17, no. 2, pp. 187–194, 1998. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Burke, A. Giannoudis, K. P. Corke et al., “Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy,” The American Journal of Pathology, vol. 163, no. 4, pp. 1233–1243, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. A. L. Mandel, B. D. Jones, J. J. La Clair, and M. D. Burkart, “A synthetic entry to pladienolide B and FD-895,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 18, pp. 5159–5164, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. A. K. Ghosh and D. D. Anderson, “Enantioselective total synthesis of pladienolide B: a potent spliceosome inhibitor,” Organic Letters, vol. 14, no. 18, pp. 4730–4733, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. R. M. Kanada, D. Itoh, M. Nagai et al., “Total synthesis of the potent antitumor macrolides pladienolide B and D,” Angewandte Chemie-International Edition, vol. 46, no. 23, pp. 4350–4355, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. V. P. Kumar and S. Chandrasekhar, “Enantioselective synthesis of pladienolide B and truncated analogues as new anticancer agents,” Organic Letters, vol. 15, no. 14, pp. 3610–3613, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Machida, Y. Aritoku, T. Nakashima, A. Arisawa, and T. Tsuchida, “Increase in pladienolide D production rate using a Streptomyces strain overexpressing a cytochrome P450 gene,” Journal of Bioscience and Bioengineering, vol. 105, no. 6, pp. 649–654, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. K. Machida, Y. Aritoku, and T. Tsuchida, “One-pot fermentation of pladienolide D by Streptomyces platensis expressing a heterologous cytochrome P450 gene,” Journal of Bioscience and Bioengineering, vol. 107, no. 6, pp. 596–598, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. S. R. Bathula, S. M. Akondi, P. S. Mainkar, and S. Chandrasekhar, “‘Pruning of biomolecules and natural products (PBNP)’: an innovative paradigm in drug discovery,” Organic and Biomolecular Chemistry, vol. 13, no. 23, pp. 6432–6448, 2015. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Salton and T. Misteli, “Small molecule modulators of pre-mRNA splicing in cancer therapy,” Trends in Molecular Medicine, vol. 22, no. 1, pp. 28–37, 2016. View at Publisher · View at Google Scholar · View at Scopus
  60. M. Seki-Asano, T. Okazaki, M. Yamagishi et al., “Isolation and characterization of a new 12-membered macrolide FD-895,” Journal of Antibiotics, vol. 47, no. 12, pp. 1395–1401, 1994. View at Publisher · View at Google Scholar · View at Scopus
  61. B. G. Isaac, S. W. Ayer, R. C. Elliott, and R. J. Stonard, “Herboxidiene: a potent phytotoxic polyketide from Streptomyces sp. A7847,” The Journal of Organic Chemistry, vol. 57, no. 26, pp. 7220–7226, 1992. View at Publisher · View at Google Scholar · View at Scopus
  62. A. J. F. Edmunds, W. Trueb, W. Oppolzer, and P. Cowley, “Herboxidiene: determination of absolute configuration by degradation and synthetic studies,” Tetrahedron, vol. 53, no. 8, pp. 2785–2802, 1997. View at Publisher · View at Google Scholar · View at Scopus
  63. A. R. Pokhrel, D. Dhakal, A. K. Jha, and J. K. Sohng, “Herboxidiene biosynthesis, production, and structural modifications: prospect for hybrids with related polyketide,” Applied Microbiology and Biotechnology, vol. 99, no. 20, pp. 8351–8362, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Sakai, T. Yoshida, K. Ochiai et al., “GEX1 compounds, novel antitumor antibiotics related to herboxidiene, produced by Streptomyces sp. I. Taxonomy, production, isolation, physicochemical properties and biological activities,” The Journal of Antibiotics, vol. 55, no. 10, pp. 855–862, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Gao, A. Vogt, C. J. Forsyth, and K. Koide, “Comparison of splicing factor 3b inhibitors in human cells,” ChemBioChem, vol. 14, no. 1, pp. 49–52, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. P. R. Blakemore, P. J. Kocieński, A. Morley, and K. Muir, “A synthesis of herboxidiene,” Journal of the Chemical Society, Perkin Transactions 1, vol. 8, pp. 955–968, 1999. View at Google Scholar
  67. M. Banwell, M. McLeod, R. Premraj, and G. Simpson, “Total synthesis of herboxidiene, a complex polyketide from Streptomyces species A7847,” Pure and Applied Chemistry, vol. 72, no. 9, pp. 1631–1634, 2000. View at Google Scholar · View at Scopus
  68. Z. Yun and J. S. Panek, “Total synthesis of herboxidiene/GEX 1A,” Organic Letters, vol. 9, no. 16, pp. 3141–3143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. T. J. Murray and C. J. Forsyth, “Total synthesis of GEX1A,” Organic Letters, vol. 10, no. 16, pp. 3429–3431, 2008. View at Publisher · View at Google Scholar
  70. M. Pellicena, K. Krämer, P. Romea, and F. Urpí, “Total synthesis of (+)-Herboxidiene from two chiral lactate-derived ketones,” Organic Letters, vol. 13, no. 19, pp. 5350–5353, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. A. K. Ghosh, N. Ma, K. A. Effenberger, and M. S. Jurica, “Total synthesis of GEX1Q1, assignment of C-5 stereoconfiguration and evaluation of spliceosome inhibitory activity,” Organic Letters, vol. 16, no. 11, pp. 3154–3157, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Lagisetti, M. V. Yermolina, L. K. Sharma, G. Palacios, B. J. Prigaro, and T. R. Webb, “Pre-mRNA splicing-modulatory pharmacophores: the total synthesis of herboxidiene, a pladienolide-herboxidiene hybrid analog and related derivatives,” ACS Chemical Biology, vol. 9, no. 3, pp. 643–648, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Koguchi, M. Nishio, J. Kotera, K. Omori, T. Ohnuki, and S. Komatsubara, “Trichostatin A and herboxidiene up-regulate the gene expression of low density lipoprotein receptor,” Journal of Antibiotics, vol. 50, no. 11, pp. 970–971, 1997. View at Publisher · View at Google Scholar · View at Scopus
  74. S. K. Hyun, S. S. Kang, K. H. Son, H. Y. Chung, and J. S. Choi, “Biflavone glucosides from Ginkgo biloba yellow leaves,” Chemical and Pharmaceutical Bulletin, vol. 53, no. 9, pp. 1200–1201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. W. Baker and W. D. Ollis, Recent Developments in the Chemistry of Natural Phenolic Compounds, Pergamon Press, London, UK, 1961.
  76. K. He, B. N. Timmermann, A. J. Aladesanmi, and L. Zeng, “A biflavonoid from Dysoxylum lenticellare gillespie,” Phytochemistry, vol. 42, no. 4, pp. 1199–1201, 1996. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Krauze-Baranowska, L. Pobłocka, and A. A. El-Hela, “Biflavones from Chamaecyparis obtusa,” Zeitschrift für Naturforschung C, vol. 60, no. 9-10, pp. 679–685, 2005. View at Google Scholar · View at Scopus
  78. M. K. Lee, S. W. Lim, H. Yang et al., “Osteoblast differentiation stimulating activity of biflavonoids from Cephalotaxus koreana,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 11, pp. 2850–2854, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Moawad, M. Hetta, J. K. Zjawiony et al., “Phytochemical investigation of Cycas circinalis and Cycas revoluta leaflets: moderately active antibacterial biflavonoids,” Planta Medica, vol. 76, no. 8, pp. 796–802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. H.-F. Zhou, C. Xie, R. Jian et al., “Biflavonoids from caper (Capparis spinosa L.) Fruits and their effects in inhibiting NF-kappa B activation,” Journal of Agricultural and Food Chemistry, vol. 59, no. 7, pp. 3060–3065, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. Z. Zhou and C. Fu, “A new flavanone and other constituents from the rhizomes of Cyperus rotundus and their antioxidant activities,” Chemistry of Natural Compounds, vol. 48, no. 6, pp. 963–965, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. J.-K. Weng and J. P. Noel, “Chemodiversity in Selaginella: a reference system for parallel and convergent metabolic evolution in terrestrial plants,” Frontiers in Plant Science, vol. 4, article 119, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. V. P. Bagla, L. J. McGaw, E. E. Elgorashi, and J. N. Eloff, “Antimicrobial activity, toxicity and selectivity index of two biflavonoids and a flavone isolated from Podocarpus henkelii (Podocarpaceae) leaves,” BMC Complementary and Alternative Medicine, vol. 14, no. 1, article 383, 2014. View at Publisher · View at Google Scholar · View at Scopus
  84. S. J. Lee, R. H. Son, H. W. Chang, S. S. Kang, and H. P. Kim, “Inhibition of arachidonate release from rat peritoneal macrophage by biflavonoids,” Archives of Pharmacal Research, vol. 20, no. 6, pp. 533–538, 1997. View at Publisher · View at Google Scholar · View at Scopus
  85. J. K. Son, M. J. Son, E. Lee et al., “Ginkgetin, a biflavone from Ginko biloba leaves, inhibits cyclooxygenases-2 and 5-lipoxygenase in mouse bone marrow-derived mast cells,” Biological and Pharmaceutical Bulletin, vol. 28, no. 12, pp. 2181–2184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. P. S. S. Yuan, “Effect of isoginkgetin on scavenge of oxygen free radical in anoxic rats,” Traditional Chinese Drug Research & Clinical Pharmacology, vol. 2, pp. 1–4, 1993. View at Google Scholar
  87. R. Saponara and E. Bosisio, “Inhibition of cAMP-phosphodiesterase by biflavones of Ginkgo biloba in rat adipose tissue,” Journal of Natural Products, vol. 61, no. 11, pp. 1386–1387, 1998. View at Publisher · View at Google Scholar · View at Scopus
  88. S. J. Lee, J. H. Choi, K. H. Son, H. W. Chang, S. S. kang, and H. P. Kim, “Suppression of mouse lymphocyte proliferation in vitro by naturally-occurring biflavonoids,” Life Sciences, vol. 57, no. 6, pp. 551–558, 1995. View at Publisher · View at Google Scholar · View at Scopus
  89. S.-J. Kim, “Effect of biflavones of Ginkgo biloba against UVB-induced cytotoxicity in vitro,” Journal of Dermatology, vol. 28, no. 4, pp. 193–199, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. S. K. Sam, J. Y. Lee, Y. K. Choi et al., “Neuroprotective effects of naturally occurring biflavonoids,” Bioorganic and Medicinal Chemistry Letters, vol. 15, no. 15, pp. 3588–3591, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. H. Sasaki, Y. Kitoh, M. Tsukada et al., “Inhibitory activities of biflavonoids against amyloid-β peptide 42 cytotoxicity in PC-12 cells,” Bioorganic and Medicinal Chemistry Letters, vol. 25, no. 14, pp. 2831–2833, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Liu, M. Grifman, J. Macdonald, P. Moller, F. Wong-Staal, and Q.-X. Li, “Isoginkgetin enhances adiponectin secretion from differentiated adiposarcoma cells via a novel pathway involving AMP-activated protein kinase,” Journal of Endocrinology, vol. 194, no. 3, pp. 569–578, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. C. R. Cederroth, M. Vinciguerra, A. Gjinovci et al., “Dietary phytoestrogens activate AMP-Activated protein kinase with improvement in lipid and glucose metabolism,” Diabetes, vol. 57, no. 5, pp. 1176–1185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Choudhary, P. Kumar, and J. Malik, “Plants and phytochemicals for Huntington's disease,” Pharmacognosy Reviews, vol. 7, no. 14, pp. 81–91, 2013. View at Publisher · View at Google Scholar · View at Scopus
  95. K. O'Brien, A. J. Matlin, A. M. Lowell, and M. J. Moore, “The biflavonoid isoginkgetin is a general inhibitor of pre-mRNA splicing,” Journal of Biological Chemistry, vol. 283, no. 48, pp. 33147–33154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. J. M. Gray, D. A. Harmin, S. A. Boswell et al., “SnapShot-Seq: a method for extracting genome-wide, in Vivo mRNA dynamics from a single total RNA sample,” PLoS ONE, vol. 9, no. 2, Article ID e89673, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. C.-K. Tseng, H.-F. Wang, A. M. Burns, M. R. Schroeder, M. Gaspari, and P. Baumann, “Human telomerase RNA processing and quality control,” Cell Reports, vol. 13, pp. 2232–2243, 2015. View at Publisher · View at Google Scholar · View at Scopus
  98. R. J. van Alphen, E. A. C. Wiemer, H. Burger, and F. A. L. M. Eskens, “The spliceosome as target for anticancer treatment,” British Journal of Cancer, vol. 100, no. 2, pp. 228–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Koga, M. Hayashi, and D. Kaida, “Splicing inhibition decreases phosphorylation level of Ser2 in Pol II CTD,” Nucleic Acids Research, vol. 43, no. 17, pp. 8258–8267, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. L. L. Hall, K. P. Smith, M. Byron, and J. B. Lawrence, “Molecular anatomy of a speckle,” The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, vol. 288, no. 7, pp. 664–675, 2006. View at Publisher · View at Google Scholar
  101. P. Loyer, J. H. Trembley, J. M. Lahti, and V. J. Kidd, “The RNP protein, RNPS1, associates with specific isoforms of the p34(cdc2)-related PITSLRE protein kinase in vivo,” Journal of Cell Science, vol. 111, no. 11, pp. 1495–1506, 1998. View at Google Scholar · View at Scopus
  102. M. Aouida, A. Eid, and M. M. Mahfouz, “CRISPR/Cas9-mediated target validation of the splicing inhibitor Pladienolide B,” Biochimie Open, 2016. View at Publisher · View at Google Scholar
  103. M. Iwata, Y. Ozawa, T. Uenaka et al., “E7107, a new urethane derivative of pladienolide D, displays curative effect against several human tumor xenografts,” Proceedings of American Association for Cancer Research, vol. 45, p. 691, 2004. View at Google Scholar
  104. E. Papaemmanuil, M. Cazzola, J. Boultwood et al., “Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts,” The New England Journal of Medicine, vol. 365, no. 15, pp. 1384–1395, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. F. Damm, F. Thol, O. Kosmider et al., “SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications,” Leukemia, vol. 26, no. 5, pp. 1137–1140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. T. R. Webb, A. S. Joyner, and P. M. Potter, “The development and application of small molecule modulators of SF3b as therapeutic agents for cancer,” Drug Discovery Today, vol. 18, no. 1-2, pp. 43–49, 2013. View at Publisher · View at Google Scholar · View at Scopus